Kuros Biosciences (KURN.SW) reported that, for the first nine months of 2025, total group revenue was $101.1 million, up by 77% compared with the same period in 2024. Revenue from Direct MagnetOs product sales rose 76% year-on-year to $99.7 million. The Group achieved an EBITDA of $7.4 million for the first nine months of 2025, up from $1.6 million in the prior-year period. Excluding tariff, adjusted EBITDA was $12.2 million compared to $6.5 million, prior year.
The Group said it is raising sales guidance and now expects growth of at least 70% for 2025.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.